Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Biogen Inc.
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC)
July 30, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease
July 30, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
DHR
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union
July 26, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Completes Acquisition of Human Immunology Biosciences
July 02, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
June 27, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
June 09, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel
June 03, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
May 30, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
May 22, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
May 16, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
IONS
Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
May 14, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Reports Progress on Corporate Responsibility Priorities
May 02, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
March 06, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
IONS
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual Meeting
March 04, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP
February 23, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
February 12, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen to Realign Resources for Alzheimer's Disease Franchise
January 31, 2024
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
December 19, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease
December 15, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
December 14, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
SAGE
Biogen Appoints Monish Patolawala to its Board of Directors
November 06, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On
October 25, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease
October 25, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
October 19, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
September 29, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Completes Acquisition of Reata Pharmaceuticals
September 26, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
RETA
LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan
September 25, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen Appoints Jane Grogan as Head of Research
September 06, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
August 04, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
Biogen to Acquire Reata Pharmaceuticals
July 28, 2023
From
Biogen Inc.
Via
GlobeNewswire
Tickers
BIIB
RETA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.